Qiagen (QIA) Stock Price, Fundamentals & Analysis

What QIA does

Qiagen (QIA) is a Healthcare stock listed on Xetra, operating in the Diagnostics & Research industry and headquartered in Venlo, Netherlands. The company provides sample-to-insight solutions that transform biological samples into molecular insights worldwide. Its product portfolio includes sample technology consumables such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies. It also offers secondary sample technology consumables, instruments for nucleic acid purification and quality control, Immune response consumables for TB testing and viral load monitoring, consumables for oncology and sexual and reproductive health, tests for genomic variants, and sample-to-insight instruments for molecular analysis and integrated PCR testing.

Key numbers explained

• Market cap of 8.04B EUR tells you the total market value of all outstanding shares; it is used to gauge the company's size relative to peers.
• Trailing P/E ratio of 22.5 reflects how much investors currently pay for each unit of past earnings; a higher number can signal growth expectations or a richer valuation.
• Forward P/E ratio of 17.4 is based on expected future earnings and can indicate how the market views upcoming performance relative to current pricing.
• Dividend yield of 0.79% shows the annual dividend income relative to the share price; the payout ratio of 18% indicates a modest portion of earnings is returned to shareholders.
• Beta of 0.63 suggests the stock has historically been less volatile than the broader market.
• 52-week range of 27.56 – 47.6 and a 1-year price change of -1.9% show the stock's recent performance context.
• Revenue of 2.1B USD with 0.3% YoY growth reflects steady top-line results.
• Profit margin of 19.5% and operating margin of 26.3% indicate healthy profitability.
• Return on equity of 11,9% measures how effectively the company generates returns on shareholders' equity.
• Debt-to-equity ratio of 49.3% shows a moderate level of leverage.
• Price-to-book ratio of 2.75 compares market value to book value.
• Next earnings date: Nov 4, 2026 is the upcoming scheduled report.

What to watch

• Industry trends: The Diagnostics & Research sector is influenced by technological advancements, regulatory changes, and healthcare spending, which can affect demand for Qiagen's products.
• Company-specific factors: Product innovation, competitive positioning, and operational efficiency are key drivers.
• Macroeconomic conditions: Interest rates, currency fluctuations, and global economic health can impact performance.
• Regulatory environment: Changes in healthcare regulations and trade policies may influence operations and profitability.